Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects

Papers of special note have been highlighted as: • of interest

References

• 1. Deans C, Maggert KA. What do you mean, ‘epigenetic’? Genetics 199(4), 887–896 (2015).
  Medline CASGoogle Scholar
• 2. Matsubara T, Toyokawa G, Takada K et al. The association and prognostic impact of enhancer of zeste homologue 2 expression and epithelial-mesenchymal transition in resected lung adenocarcinoma. PLOS ONE 14(5), e0215103 (2019).
  MedlineGoogle Scholar
• 3. Wu X, Scott H, Carlsson SV et al. Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. Prostate 79(10), 1079–1089 (2019).
  Medline CASGoogle Scholar
• 4. Bachmann IM, Halvorsen OJ, Collett K et al. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24(2), 268–273 (2006).
  Medline CASGoogle Scholar
• 5. Huqun, Ishikawa R, Zhang J et al. Enhancer of zeste homolog 2 is a novel prognostic biomarker in non small cell lung cancer. Cancer 118(6), 1599–1606 (2012).
  Medline CASGoogle Scholar
• 6. Morin RD, Johnson NA, Severson TM et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42(2), 181–185 (2010).
  Medline CASGoogle Scholar
• 7. Yamagishi M, Uchimaru K. Targeting EZH2 in cancer therapy. Curr. Opin. Oncol. 29(5), 375–381 (2017).
  Medline CASGoogle Scholar
• 8. Kim KH, Roberts CWM. Targeting EZH2 in cancer. Nat. Med. 22(2), 128–134 (2016).
  Medline CASGoogle Scholar
• 9. Wan D, Han X, Zhang C, Zhang Y, Ma Y, Wang G. EZH2 promotes the progression of osteosarcoma through the activation of the AKT/GSK3β pathway. Clin. Exp. Pharmacol. Physiol. 49(11), 1179–1186 (2022).
  Medline CASGoogle Scholar
• 10. Gong H, Li Y, Yuan Y et al. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells. BMC Cancer 20(1), 1189 (2020).
  Medline CASGoogle Scholar
• 11. Italiano A, Soria J-C, Toulmonde M et al. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 19(5), 649–659 (2018).
  Medline CASGoogle Scholar
• 12. Shen L, Zhou Y, He H et al. Crosstalk between macrophages, T cells, and iron metabolism in tumor microenvironment. Oxid. Med. Cell Longev. 2021, 8865791 (2021).
  MedlineGoogle Scholar
• 13. Tumes DJ, Onodera A, Suzuki A et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. Immunity 39(5), 819–832 (2013).
  Medline CASGoogle Scholar
• 14. Peng D, Kryczek I, Nagarsheth N et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527(7577), 249–253 (2015).
  Medline CASGoogle Scholar
• 15. Zingg D, Arenas-Ramirez N, Sahin D et al. The histone methyltransferase Ezh2 controls mechanisms of adaptive resistance to tumor immunotherapy. Cell Rep. 20(4), 854–867 (2017).
  Medline CASGoogle Scholar
• 16. Nagarsheth N, Peng D, Kryczek I et al. PRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancer. Cancer Res. 76(2), 275–282 (2016).
  Medline CASGoogle Scholar
• 17. Chen G, Subedi K, Chakraborty S et al. Ezh2 regulates activation-induced CD8⁺ T cell cycle progression via repressing Cdkn2a and Cdkn1c expression. Front Immunol. 9, 549 (2018).
  MedlineGoogle Scholar
• 18. Chang JT, Wherry EJ, Goldrath AW. Molecular regulation of effector and memory T cell differentiation. Nat. Immunol. 15(12), 1104–1115 (2014).
  Medline CASGoogle Scholar
• 19. Kaech SM, Cui W. Transcriptional control of effector and memory CD8⁺ T cell differentiation. Nat. Rev. Immunol. 12(11), 749–761 (2012).
  Medline CASGoogle Scholar
• 20. He S, Liu Y, Meng L et al. Ezh2 phosphorylation state determines its capacity to maintain CD8⁺ T memory precursors for antitumor immunity. Nat. Commun. 8(1), 2125 (2017).
  MedlineGoogle Scholar
• 21. Kim EH, Suresh M. Role of PI3K/Akt signaling in memory CD8 T cell differentiation. Front Immunol. 4, 20 (2013).
  MedlineGoogle Scholar
• 22. Zhao E, Maj T, Kryczek I et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat. Immunol. 17(1), 95–103 (2016).
  Medline CASGoogle Scholar
• 23. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057–1061 (2003).
  Medline CASGoogle Scholar
• 24. Yang X-P, Jiang K, Hirahara K et al. EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion. Sci. Rep. 5, 10643 (2015).
  Medline CASGoogle Scholar
• 25. Arvey A, van der Veeken J, Samstein RM, Feng Y, Stamatoyannopoulos JA, Rudensky AY. Inflammation-induced repression of chromatin bound by the transcription factor Foxp3 in regulatory T cells. Nat. Immunol. 15(6), 580–587 (2014).
  Medline CASGoogle Scholar
• 26. Kwon H-K, Chen H-M, Mathis D, Benoist C. Different molecular complexes that mediate transcriptional induction and repression by FoxP3. Nat. Immunol. 18(11), 1238–1248 (2017).
  Medline CASGoogle Scholar
• 27. DuPage M, Chopra G, Quiros J et al. The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation. Immunity 42(2), 227–238 (2015).
  Medline CASGoogle Scholar
• 28. Wang D, Quiros J, Mahuron K et al. Targeting EZH2 reprograms intratumoral regulatory T cells to enhance cancer immunity. Cell Rep. 23(11), 3262–3274 (2018).
  Medline CASGoogle Scholar
• 29. Guillerey C, Smyth MJ et al. NK Cells and Cancer Immunoediting. Curr. Top. Microbiol. Immunol. 395, Issue 115–45 (2016).
  Medline CASGoogle Scholar
• 30. Bugide S, Green MR, Wajapeyee N. Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells. Proc. Natl Acad. Sci. USA 115(15), E3509–E3518 (2018).
  Medline CASGoogle Scholar
• 31. Ramakrishnan S, Granger V, Rak M et al. Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer. Cell Death Differ. 26(10), 2100–2114 (2019).
  Medline CASGoogle Scholar
• 32. Bugide S, Gupta R, Green MR, Wajapeyee N. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner. Proc. Natl Acad. Sci. USA 118(30), e2102718118 (2021).
  Medline CASGoogle Scholar
• 33. Yu M, Su Z, Huang X et al. Histone methyltransferase Ezh2 negatively regulates NK cell terminal maturation and function. J. Leukoc. Biol. 110(6), 1033–1045 (2021).
  Medline CASGoogle Scholar
• 34. Yin J, Leavenworth JW, Li Y et al. Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc. Natl Acad. Sci. USA 112(52), 15988–15993 (2015).
  Medline CASGoogle Scholar
• 35. Velichutina I, Shaknovich R, Geng H et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 116(24), 5247–5255 (2010).
  Medline CASGoogle Scholar
• 36. Béguelin W, Rivas MA, Calvo Fernández MT et al. EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nat. Commun. 8(1), 877 (2017).
  MedlineGoogle Scholar
• 37. Béguelin W, Popovic R, Teater M et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 23(5), 677–692 (2013).
  Medline CASGoogle Scholar
• 38. Caganova M, Carrisi C, Varano G et al. Germinal center dysregulation by histone methyltransferase EZH2 promotes lymphomagenesis. J. Clin. Invest. 123(12), 5009–5022 (2013).
  Medline CASGoogle Scholar
• 39. Ennishi D, Takata K, Béguelin W et al. Molecular and genetic characterization of MHC deficiency identifies EZH2 as therapeutic target for enhancing immune recognition. Cancer Discov. 9(4), 546–563 (2019).
  MedlineGoogle Scholar
• 40. Yuan H, Nishikori M, Otsuka Y, Arima H, Kitawaki T, Takaori-Kondo A. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment. Cancer Sci. 112(11), 4604–4616 (2021).
  Medline CASGoogle Scholar
• 41. Cabrita R, Lauss M, Sanna A et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577(7791), 561–565 (2020).
  Medline CASGoogle Scholar
• 42. Petitprez F, de Reyniès A, Keung EZ et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577(7791), 556–560 (2020).
  Medline CASGoogle Scholar
• 43. Helmink BA, Reddy SM, Gao J et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791), 549–555 (2020).
  Medline CASGoogle Scholar
• 44. Kalluri R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16(9), 582–598 (2016).
  Medline CASGoogle Scholar
• 45. Huang B, Huang M, Li Q. Cancer-associated fibroblasts promote angiogenesis of hepatocellular carcinoma by VEGF-mediated EZH2/VASH1 pathway. Technol. Cancer Res. Treat. 18, 1533033819879905 (2019).
  Google Scholar
• 46. Maeda M, Takeshima H, Iida N et al. Cancer cell niche factors secreted from cancer-associated fibroblast by loss of H3K27me3. Gut 69(2), 243–251 (2020).
  Medline CASGoogle Scholar
• 47. Yasuda T, Koiwa M, Yonemura A et al. Inflammation-driven senescence-associated secretory phenotype in cancer-associated fibroblasts enhances peritoneal dissemination. Cell Rep. 34(8), 108779 (2021).
  Medline CASGoogle Scholar
• 48. Gorgoulis V, Adams PD, Alimonti A et al. Cellular senescence: defining a path forward. Cell 179(4), 813–827 (2019).
  Medline CASGoogle Scholar
• 49. Kelly J, Ali Khan A, Yin J, Ferguson TA, Apte RS. Senescence regulates macrophage activation and angiogenic fate at sites of tissue injury in mice. J. Clin. Invest. 117(11), 3421–3426 (2007).
  Medline CASGoogle Scholar
• 50. Ruhland MK, Loza AJ, Capietto A-H et al. Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis. Nat. Commun. 7, 11762 (2016).
  Medline CASGoogle Scholar
• 51. Corzo CA, Condamine T, Lu L et al. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207(11), 2439–2453 (2010).
  Medline CASGoogle Scholar
• 52. Tamura R, Tanaka T, Yamamoto Y, Akasaki Y, Sasaki H. Dual role of macrophage in tumor immunity. Immunotherapy 10(10), 899–909 (2018).
  CASGoogle Scholar
• 53. Ruffell B, Chang-Strachan D, Chan V et al. Macrophage IL-10 blocks CD8⁺ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell 26(5), 623–637 (2014).
  Medline CASGoogle Scholar
• 54. McIntire RH, Morales PJ, Petroff MG, Colonna M, Hunt JS. Recombinant HLA-G5 and -G6 drive U937 myelomonocytic cell production of TGF-beta1. J. Leukoc. Biol. 76(6), 1220–1228 (2004).
  Medline CASGoogle Scholar
• 55. Zheng Y, Wang Z, Wei S, Liu Z, Chen G. Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer. Cancer Lett. 499, 148–163 (2021).
  Medline CASGoogle Scholar
• 56. Yin Y, Qiu S, Li X, Huang B, Xu Y, Peng Y. EZH2 suppression in glioblastoma shifts microglia toward M1 phenotype in tumor microenvironment. J. Neuroinflammation 14(1), 220 (2017).
  MedlineGoogle Scholar
• 57. Li C, Song J, Guo Z et al. EZH2 inhibitors suppress colorectal cancer by regulating macrophage polarization in the tumor microenvironment. Front Immunol. 13, 857808 (2022). • Provides evidence that EZH2 inhibitors can remodel the tumor microenvironment by regulating macrophage polarization.
  Medline CASGoogle Scholar
• 58. Gulati N, Béguelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk. Lymphoma 59(7), 1574–1585 (2018).
  Medline CASGoogle Scholar
• 59. Huang S, Wang Z, Zhou J et al. EZH2 inhibitor GSK126 suppresses antitumor immunity by driving production of myeloid-derived suppressor cells. Cancer Res. 79(8), 2009–2020 (2019).
  Medline CASGoogle Scholar
• 60. Rosenthal R, Cadieux EL, Salgado R et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567(7749), 479–485 (2019).
  Medline CASGoogle Scholar
• 61. Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr. Opin. Immunol. 39, 44–51 (2016).
  Medline CASGoogle Scholar
• 62. Zhao Y, Wang X-X, Wu W et al. EZH2 regulates PD-L1 expression via HIF-1α in non-small cell lung cancer cells. Biochem. Biophys. Res. Commun. 517(2), 201–209 (2019).
  Medline CASGoogle Scholar
• 63. Xia L, Zhu X, Zhang L, Xu Y, Chen G, Luo J. EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer. Biotechnol. Appl. Biochem. 67(6), 1011–1019 (2020).
  Medline CASGoogle Scholar
• 64. Susek KH, Karvouni M, Alici E, Lundqvist A. The role of CXC chemokine receptors 1–4 on immune cells in the tumor microenvironment. Front. Immunol. 9, 2159 (2018).
  MedlineGoogle Scholar
• 65. Wennerberg E, Kremer V, Childs R, Lundqvist A. CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo. Cancer Immunol. Immunother. 64(2), 225–235 (2015).
  Medline CASGoogle Scholar
• 66. Pang B, Zheng X-R, Tian J-X et al. EZH2 promotes metabolic reprogramming in glioblastomas through epigenetic repression of EAF2–HIF1α signaling. Oncotarget 7(29), 45134–45143 (2016).
  MedlineGoogle Scholar
• 67. Zhou L, Mudianto T, Ma X, Riley R, Uppaluri R. Targeting EZH2 enhances antigen presentation, antitumor immunity, and circumvents anti-PD-1 resistance in head and neck cancer. Clin. Cancer Res. 26(1), 290–300 (2020).
  Medline CASGoogle Scholar
• 68. Qiu F, Yang Q, Sun W, Ruan K, Jiang N, Zhou J. EZH2 inhibition activates dsRNA–interferon axis stress and promotes response to PD-1 checkpoint blockade in NSCLC. J. Cancer 13(9), 2893–2904 (2022).
  Medline CASGoogle Scholar
• 69. Goswami S, Apostolou I, Zhang J et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 128(9), 3813–3818 (2018).
  MedlineGoogle Scholar
• 70. Emran AA, Chatterjee A, Rodger EJ et al. Targeting DNA methylation and EZH2 activity to overcome melanoma resistance to immunotherapy. Trends Immunol. 40(4), 328–344 (2019).
  Medline CASGoogle Scholar
• 71. Hong YK, Li Y, Pandit H et al. Epigenetic modulation enhances immunotherapy for hepatocellular carcinoma. Cell. Immunol. 336, 66–74 (2019).
  Medline CASGoogle Scholar
• 72. Kailayangiri S, Altvater B, Lesch S et al. EZH2 inhibition in Ewing sarcoma upregulates GD2 expression for targeting with gene-modified T cells. Mol. Ther. 27(5), 933–946 (2019).
  Medline CASGoogle Scholar
• 73. Vaughan S, Coward JI, Bast RC et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11(10), 719–25 (2011).
  Medline CASGoogle Scholar
• 74. Saxena M, Stephens MA, Pathak H, Rangarajan A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2(7), e179 (2011).
  Medline CASGoogle Scholar
• 75. Gardner EE, Lok BH, Schneeberger VE et al. Chemosensitive relapse in small cell lung cancer proceeds through an EZH2–SLFN11 axis. Cancer Cell 31(2), 286–299 (2017).
  Medline CASGoogle Scholar
• 76. Fillmore CM, Xu C, Desai PT et al. EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors. Nature 520(7546), 239–242 (2015).
  Medline CASGoogle Scholar
• 77. Zhou S, Peng J, Xiao L et al. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. Cell Death Dis. 12(5), 463 (2021).
  Medline CASGoogle Scholar
• 78. Qiu X, Wang W, Li B et al. Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. BMC Cancer 19(1), 27 (2019).
  MedlineGoogle Scholar
• 79. Avan A, Crea F, Paolicchi E et al. Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. Mol. Cancer Ther. 11(8), 1735–1746 (2012).
  Medline CASGoogle Scholar
• 80. Vincent J, Mignot G, Chalmin F et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70(8), 3052–3061 (2010).
  Medline CASGoogle Scholar
• 81. Fan T-Y, Wang H, Xiang P et al. Inhibition of EZH2 reverses chemotherapeutic drug TMZ chemosensitivity in glioblastoma. Int. J. Clin. Exp. Pathol. 7(10), 6662–6670 (2014).
  Medline CASGoogle Scholar
• 82. Smits KM, Melotte V, Niessen HEC et al. Epigenetics in radiotherapy: where are we heading? Radiother. Oncol. 111(2), 168–177 (2014).
  MedlineGoogle Scholar
• 83. Watanabe S, Kuwabara Y, Suehiro S et al. Valproic acid reduces hair loss and improves survival in patients receiving temozolomide-based radiation therapy for high-grade glioma. Eur. J. Clin. Pharmacol. 73(3), 357–363 (2017).
  Medline CASGoogle Scholar
• 84. Sharda A, Rashid M, Shah SG et al. Elevated HDAC activity and altered histone phospho-acetylation confer acquired radio-resistant phenotype to breast cancer cells. Clin. Epigenetics 12(1), 4 (2020).
  MedlineGoogle Scholar
• 85. Zhu X, Wang Y, Tan L, Fu X. The pivotal role of DNA methylation in the radio-sensitivity of tumor radiotherapy. Cancer Med. 7(8), 3812–3819 (2018).
  Medline CASGoogle Scholar
• 86. Wang J, Zhou F, Li Z et al. Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. Sci. Rep. 8(1), 998 (2018).
  MedlineGoogle Scholar
• 87. Sak A, Kübler D, Bannik K et al. Epigenetic silencing and activation of transcription: influence on the radiation sensitivity of glioma cell lines. Int. J. Radiat. Biol. 93(5), 494–506 (2017).
  Medline CASGoogle Scholar
• 88. Alimova I, Birks DK, Harris PS et al. Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. Neuro. Oncol. 15(2), 149–160 (2013).
  Medline CASGoogle Scholar
• 89. Agrawal R, Chen M, Bukhari Z, Ogunwobi OO, Haseeb MA, Martello LA. EZH2 downregulation augments the effect of irradiation in reducing pancreatic cancer cell proliferation in vitro. Ann. Clin. Lab. Sci. 50(1), 45–56 (2020).
  Medline CASGoogle Scholar
• 90. Cai M-Y, Tong Z-T, Zhu W et al. H3K27me3 protein is a promising predictive biomarker of patients’ survival and chemoradioresistance in human nasopharyngeal carcinoma. Mol. Med. 17(11-12), 1137–1145 (2011).
  Medline CASGoogle Scholar
• 91. Gounder MM, Zhu G, Roshal L et al. Immunologic correlates of the abscopal effect in a SMARCB1/INI1-negative poorly differentiated chordoma after EZH2 inhibition and radiotherapy. Clin. Cancer Res. 25(7), 2064–2071 (2019).
  Medline CASGoogle Scholar
• 92. Huang X, Yan J, Zhang M et al. Targeting epigenetic crosstalk as a therapeutic strategy for EZH2-aberrant solid tumors. Cell 175(1), 186–199.e19 (2018). • Elucidates the epigenetic mechanism of EZH2 inhibitor resistance and provides a three-drug combination regimen with robust efficacy.
  Medline CASGoogle Scholar
• 93. Zhang Y, Dong W, Zhu J, Wang L, Wu X, Shan H. Combination of EZH2 inhibitor and BET inhibitor for treatment of diffuse intrinsic pontine glioma. Cell Biosci. 7, 56 (2017).
  MedlineGoogle Scholar
• 94. Zhang L, Li H-T, Shereda R et al. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. Cancer Lett. 548, 215899 (2022).
  Medline CASGoogle Scholar
• 95. Wang X, Wang D, Ding N et al. The synergistic anti-tumor activity of EZH2 inhibitor SHR2554 and HDAC inhibitor chidamide through ORC1 reduction of DNA replication process in diffuse large B cell lymphoma. Cancers (Basel) 13(17), 4249 (2021).
  Medline CASGoogle Scholar
• 96. Lue JK, Prabhu SA, Liu Y et al. Precision targeting with EZH2 and HDAC inhibitors in epigenetically dysregulated lymphomas. Clin. Cancer Res. 25(17), 5271–5283 (2019).
  Medline CASGoogle Scholar
• 97. Wang Y, Chen SY, Colborne S et al. Histone deacetylase inhibitors synergize with catalytic inhibitors of EZH2 to exhibit antitumor activity in small cell carcinoma of the ovary, hypercalcemic type. Mol. Cancer Ther. 17(12), 2767–2779 (2018).
  Medline CASGoogle Scholar
• 98. Takashina T, Kinoshita I, Kikuchi J et al. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Cancer Sci. 107(7), 955–962 (2016).
  Medline CASGoogle Scholar
• 99. Ye M, Gao R, Chen S et al. Downregulation of MEG3 and upregulation of EZH2 cooperatively promote neuroblastoma progression. J. Cell Mol. Med. 26(8), 2377–2391 (2022).
  Medline CASGoogle Scholar
• 100. Casciello F, Kelly GM, Ramarao-Milne P et al. Combined inhibition of G9a and EZH2 suppresses tumor growth via synergistic induction of IL24-mediated apoptosis. Cancer Res. 82(7), 1208–1221 (2022).
  Medline CASGoogle Scholar
• 101. Spiliopoulou P, Spear S, Mirza H et al. Dual G9A/EZH2 inhibition stimulates antitumor immune response in ovarian high-grade serous carcinoma. Mol. Cancer Ther. 21(4), 522–534 (2022).
  MedlineGoogle Scholar
• 102. Pan M, Reid MA, Lowman XH et al. Regional glutamine deficiency in tumours promotes dedifferentiation through inhibition of histone demethylation. Nat. Cell Biol. 18(10), 1090–1101 (2016).
  Medline CASGoogle Scholar
• 103. Yu H, Ma M, Yan J et al. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy. J. Transl. Med. 15(1), 243 (2017).
  Medline CASGoogle Scholar
• 104. Fu H, Cheng L, Sa R, Jin Y, Chen L. Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF_V600E by synergistically decreasing global trimethylation of H3K27. J. Cell Mol. Med. 24(6), 3336–3345 (2020).
  Medline CASGoogle Scholar
• 105. Terranova CJ, Tang M, Maitituoheti M et al. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Rep. 36(3), 109410 (2021).
  Medline CASGoogle Scholar
• 106. Quan C, Chen Y, Wang X et al. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer. Cancer Lett. 495, 41–52 (2020).
  Medline CASGoogle Scholar
• 107. Karakashev S, Fukumoto T, Zhao B et al. EZH2 inhibition sensitizes CARM1-high, homologous recombination proficient ovarian cancers to PARP inhibition. Cancer Cell 37(2), 157–167.e6 (2020).
  Medline CASGoogle Scholar
• 108. Yamaguchi H, Du Y, Nakai K et al. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Oncogene 37(2), 208–217 (2018).
  Medline CASGoogle Scholar
• 109. Rondinelli B, Gogola E, Yücel H et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat. Cell Biol. 19(11), 1371–1378 (2017).
  Medline CASGoogle Scholar
• 110. Zitvogel L, Galluzzi L, Kepp O, Smyth MJ, Kroemer G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15(7), 405–414 (2015).
  Medline CASGoogle Scholar
• 111. Xu T, Dai J, Tang L et al. EZH2 inhibitor enhances the STING agonist-induced antitumor immunity in melanoma. J. Invest. Dermatol. 142(4), 1158–1170.e8 (2022).
  Medline CASGoogle Scholar
• 112. Xing H, Gao M, Wang Y et al. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma. Clin. Transl. Med. 12(5), e835 (2022).
  Medline CASGoogle Scholar
• 113. Rehman H, Chandrashekar DS, Balabhadrapatruni C et al. ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors. JCI Insight 7(16), e155899 (2022).
  MedlineGoogle Scholar
• 114. Chen F, Liu J, Song X et al. EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition. Cancer Lett. 524, 151–160 (2022).
  Medline CASGoogle Scholar
• 115. Selmin OI, Fang C, Lyon AM et al. Inactivation of adenomatous polyposis coli reduces bile acid/farnesoid X receptor expression through Fxr gene CpG methylation in mouse colon tumors and human colon cancer cells. J. Nutr. 146(2), 236–242 (2016).
  Medline CASGoogle Scholar
• 116. Yu J, Yang K, Zheng J et al. Activation of FXR and inhibition of EZH2 synergistically inhibit colorectal cancer through cooperatively accelerating FXR nuclear location and upregulating CDX2 expression. Cell Death Dis. 13(4), 388 (2022). • Explores the possibility of combining an EZH2 inhibitor with a metabolism-modulating drug in cancer treatment.
  Medline CASGoogle Scholar
• 117. Zhang T, Guo Z, Huo X et al. Dysregulated lipid metabolism blunts the sensitivity of cancer cells to EZH2 inhibitor. EBioMedicine 77, 103872 (2022).
  Medline CASGoogle Scholar
• 118. Wu Y, Zhang Z, Cenciarini ME et al. Tamoxifen resistance in breast cancer is regulated by the EZH2–ERα–GREB1 transcriptional axis. Cancer Res. 78(3), 671–684 (2018).
  Medline CASGoogle Scholar
• 119. Kumari K, Kumar S, Parida DK, Mishra SK. EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen. Breast Cancer 28(2), 355–367 (2021).
  MedlineGoogle Scholar
• 120. Shankar E, Franco D, Iqbal O, Moreton S, Kanwal R, Gupta S. Dual targeting of EZH2 and androgen receptor as a novel therapy for castration-resistant prostate cancer. Toxicol. Appl. Pharmacol. 404, 115200 (2020).
  Medline CASGoogle Scholar
• 121. Bai Y, Zhang Z, Cheng L et al. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer. J. Biol. Chem. 294(25), 9911–9923 (2019).
  Medline CASGoogle Scholar
• 122. Morel D, Jeffery D, Aspeslagh S, Almouzni G, Postel-Vinay S. Combining epigenetic drugs with other therapies for solid tumours – past lessons and future promise. Nat. Rev. Clin. Oncol. 17(2), 91–107 (2020). • Review on epigenetic drugs combined with other therapies for solid tumors.
  Medline CASGoogle Scholar